New report shines spotlight on Canadian isotope excellence

Medical isotope ecosystem directory details tremendous capabilities of Canada’s isotope industry.   Today, the Organization of Canadian Nuclear Industries (OCNI) and the Canadian Nuclear Isotope Council (CNIC) released the Canadian Medical Isotope Ecosystem Directory. The directory demonstrates the capabilities of the Canadian isotope sector companies and their leading international expertise as well as highlights the […]   READ MORE

Canada is an Isotope Superpower

On the CNIC’s 3rd birthday we highlight why the isotope sector is key contributor to economic recovery. The importance of nuclear medicine and medical isotopes in our daily lives — and Canada’s global leadership position in this sector — admittedly flies under the radar for most people, and their significance has never been more vital […]   READ MORE

Storied Canadian manufacturer, Advanced Cyclotron Systems, joins the CNIC

TORONTO – March 31, 2021 – Advanced Cyclotron Systems Inc. (ACSI), a world leader in the design and manufacturing of cyclotron equipment, including PET and SPECT radioisotope production cyclotrons, will join the Canadian Nuclear Isotope Council (CNIC), further cementing the industry association as the pre-eminent representative of the Canadian Isotope sector. “Over the past two-and-half […]   READ MORE

CNIC and Bangor University partner to export Canadian isotope sector expertise following digital trade mission

TORONTO – March 30, 2021 – Following a market study completed in March 2020, the Welsh government worked with the Organization of Canadian Nuclear Industries, the Canadian Nuclear Association, and Natural Resources Canada on a digital trade mission. The four-day event explored bilateral opportunities in Canada, the UK, and other markets of interest for Welsh […]   READ MORE

CPDC Announces First Patient Dosed in a Phase 3 Clinical Trial of a Prostate Cancer Diagnostic Imaging Product, [18F]PSMA-1007

Hamilton, Ontario, February 24, 2021 – The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, is announcing today that the first patient has been dosed and imaged in a Phase 3 trial for [18F]PSMA-1007. This diagnostic imaging product is a positron-emitting tomography (PET) agent that […]   READ MORE